Kim Pottkämper, www.kimoment.de
A milestone for cold plasma medicine!
Coldplasmatech GmbH, a pioneer in the development of medical cold plasma technology, has announced a groundbreaking partnership with the US company Royal Biologics. The goal: the international distribution of a German high technology for the treatment of chronic and infected wounds.
Click here for the official press release: CPT x Royal press release final
Why this partnership is important:
Chronic wounds are one of the biggest medical challenges worldwide. Around one billion people are affected and the costs for healthcare systems are enormous - over 50 billion US dollars a year in the USA alone. Conventional treatment methods often reach their limits, especially when dealing with multi-resistant germs.
Coldplasmatech has developed an innovative solution with its CPT® technology: cold atmospheric plasma (CAP), which is applied directly to the wound. The treatment is non-invasive, painless, has an antibacterial effect - and promotes natural wound healing at cellular level.
What Royal Biologics brings to the table:
Royal Biologics is a leading US company in the field of orthobiologics and advanced wound care. Backed by private equity, Royal not only brings a strong distribution network and many years of market experience, but also makes targeted investments in pioneering technologies such as those of Coldplasmatech GmbH. Together, the two companies are now pursuing the goal of making cold plasma medicine available worldwide
What this means for the future:
This partnership is a milestone: for the first time, a scientifically validated cold plasma therapy developed in Germany will be scalable worldwide by an innovation-oriented US company. This step marks the beginning of a new era in wound care - with direct benefits for patients, healthcare professionals and healthcare systems.
